Compare REPL & XMTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REPL | XMTR |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 4.2B |
| IPO Year | 2018 | 2021 |
| Metric | REPL | XMTR |
|---|---|---|
| Price | $12.92 | $86.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $5.67 | ★ $58.60 |
| AVG Volume (30 Days) | ★ 2.4M | 442.7K |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.95 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $686,631,000.00 |
| Revenue This Year | N/A | $23.76 |
| Revenue Next Year | N/A | $18.38 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.87 |
| 52 Week Low | $1.50 | $35.86 |
| 52 Week High | $16.33 | $106.08 |
| Indicator | REPL | XMTR |
|---|---|---|
| Relative Strength Index (RSI) | 44.13 | 41.13 |
| Support Level | $6.81 | $79.58 |
| Resistance Level | $16.02 | $98.35 |
| Average True Range (ATR) | 0.79 | 4.39 |
| MACD | -0.37 | -0.41 |
| Stochastic Oscillator | 0.96 | 19.69 |
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.